Effects of toxic doses of glutamate on Cu-Zn and Mn/superoxide dismutases activities in human glioma cell lines.
Recent research has implicated glutamate in the growth and invasive migration of gliomas. Superoxide dismutase (SOD) is involved in excitotoxicity and may influence cellular proliferative status. Thus, this study investigated the effects of gliotoxic doses of glutamate on Cu-Zn and Mn/SODs activities in human glioma cell lines. To this end, glioma cell lines (U87MG, U138MG and U251MG) were treated with glutamate (5-200 mM) during 48 h. Then, cell viability assays, clonogenic assay and Cu-Zn and Mn/SODs activities of the cell lines were performed. IC50values of glutamate were similar for both U87MG and U138MG cells (56 and 69 mM, respectively), while a higher value was detected for U251MG cells (110 mM). In the long term, 14 days after glutamate was removed from the culture media, cells showed partial or complete recovery. The effects of glutamate treatment on Cu-Zn and Mn/SODs activities varied among the distinct cell lines. While acute treatment with toxic doses of glutamate caused a significant decrease in the Cu-Zn/SOD activity of U138MG and U251MG cells, it did not affect Cu-Zn/SOD activity in U87MG cells. Only in U251MG cells, acute glutamate treatment decreased significantly Mn/SOD activity. In the long term (14 days after the 48 h treatment), glutamate did not affect either Cu-Zn or Mn/SODs activities. Thus, it may be suggested that SOD vulnerability to glutamate-mediated effects may be related to distinct tumoral cell behavior.
Regner
Andrea
A
Centro de Pesquisas em Ciências Médicas, Universidade Luterana do Brasil (ULBRA), Rua Miguel Tostes, 101, Prédio 22, 5 andar, Bairro São Luis, Canoas/RS, CEP: 9240-280 Brasil. regner@uol.com.br
Schunemann
Daniel Pretto
DP
Grivicich
Ivana
I
Diel
Celito Luis
CL
Farias
Caroline Brunetto
CB
Kowaleski
Giovana
G
Mondadori
Edlaine
E
Schwartsmann
Gilberto
G
da Rocha
Adriana Brondani
AB
D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005910:Glioma / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D018698:Glutamic Acid / Q000494:pharmacology*; D006801:Humans; D020128:Inhibitory Concentration 50; D009423:Nervous System Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D009498:Neurotoxins / Q000494:pharmacology; D013482:Superoxide Dismutase / Q000187:drug effects*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009498:Neurotoxins; D018698:Glutamic Acid; D013482:Superoxide Dismutase
J Neurochem. 2000 Oct;75(4):1557-65
10987836
J Neurosci. 1999 Dec 15;19(24):10767-77
10594060
Nature. 1970 Aug 15;227(5259):680-5
5432063
Int J Cancer. 1997 Oct 9;73(2):187-92
9335440
J Neurosci Res. 1998 May 1;52(3):307-21
9590439
J Neurosci. 1996 Aug 15;16(16):5073-81
8756437
J Neurotrauma. 2001 Aug;18(8):783-92
11526984
J Neurochem. 1985 Oct;45(4):1186-92
2863331
Prog Neurobiol. 2001 Sep;65(1):1-105
11369436
Cancer Res. 2001 Aug 15;61(16):6082-8
11507057
J Neuroimmunol. 1997 Sep;78(1-2):152-61
9307240
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8530-5
8710904
Physiol Rev. 1998 Jan;78(1):99-141
9457170
Neurosurgery. 2000 Feb;46(2):419-30
10690732
Int J Dev Neurosci. 2000 Apr-Jun;18(2-3):289-97
10715583
J Neurosci Methods. 2002 Jan 15;113(1):99-110
11741727
Prog Neurobiol. 2000 Dec;62(6):561-81
10880851
J Neurochem. 2000 Apr;74(4):1666-73
10737625
Cancer Res. 2003 Mar 15;63(6):1297-303
12649190
Exp Neurol. 1999 Aug;158(2):428-36
10415149
Annu Rev Neurosci. 1990;13:171-82
1970230
Cancer Res. 2000 Jul 15;60(14):3927-39
10919671
FEBS Lett. 2001 May 18;497(1):1-5
11376653
J Neurosci Res. 1999 Aug 15;57(4):417-28
10440891
Brain Res. 1998 Dec 14;814(1-2):164-70
9838093
J Neurochem. 2000 Sep;75(3):939-45
10936174
J Neurooncol. 1996 Aug;29(2):121-8
8858516
N Engl J Med. 1994 Mar 3;330(9):613-22
7905600
Brain Res. 1997 Aug 22;766(1-2):285-8
9359618
Am J Physiol. 1997 Nov;273(5 Pt 2):R1771-8
9374822
Neurosurgery. 1997 Nov;41(5):1146-50; discussion 1151
9361070
Eur J Pharmacol. 2002 Jul 5;447(2-3):239-46
12151015
J Cereb Blood Flow Metab. 2000 Feb;20(2):359-68
10698074
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6372-7
11331750
Nat Med. 2001 Sep;7(9):1010-5
11533703
J Biol Chem. 1997 Jul 25;272(30):18515-7
9228011
Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3113-7
8464931
Neuron. 1994 Sep;13(3):713-25
7917301
Cancer Res. 2002 Feb 15;62(4):1205-12
11861405
Respir Physiol. 2001 Dec;129(1-2):71-81
11738647
Anal Biochem. 1976 May 7;72:248-54
942051
Oncologist. 2002;7(1):17-33
11854544
Cancer Res. 1999 Sep 1;59(17):4383-91
10485487
News Physiol Sci. 1999 Oct;14:177-182
11390847
Brain Res. 1998 Apr 6;789(1):32-9
9602043
Clin Cancer Res. 2000 Jun;6(6):2513-20
10873107